Publications by authors named "M Wiedig"

Claim this Profile
[
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.
Philippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, Ahmad Awada, Ghanem Ghanem

Int J Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].
Mohammad Krayem, Fabrice Journe, Murielle Wiedig, Renato Morandini, Ahmad Najem

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Mohammad Krayem, Fabrice Journe, Murielle Wiedig, Renato Morandini, Ahmad Najem

Eur J Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Mohammad Krayem, Fabrice Journe, Murielle Wiedig, Renato Morandini, François Sales

Eur J Cancer· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles.
Philippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, Ahmad Awada, Ghanem Ghanem

Int J Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis